PPA
SEEL

Parametric Portfolio Associates’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Parametric Portfolio Associates’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7
Closed -$46K – 3778
2021
Q4 		$46K Buy
7
+2
+40% +$15.4K ﹤0.01% 3601
2021
Q3 		$48K Sell
5
-3
-38% -$25.8K ﹤0.01% 3578
2021
Q2 		$78K Buy
+8
New +$131K ﹤0.01% 3507

Other funds holding SEEL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $1.07B AUM 34.04% 1-Year Est. Return

Parametric Portfolio Associates's SEEL Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2022, closing a stake of 7 shares — an estimated $46K sold.

Parametric Portfolio Associates first reported a position in SEEL in Q2 2021 and held it in 3 quarters. The position peaked at $78K in Q2 2021. 77 funds tracked by Wall St. Rank hold SEEL as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 7 Seelos Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $46K.
  • Parametric Portfolio Associates first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Parametric Portfolio Associates's Seelos Therapeutics, Inc. Common Stock position peaked at $78K in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.